Red-back spider (Latrodectus hasselti) antivenom prevents the toxicity of widow spider venoms

DSpace/Manakin Repository

Search OPUS


Advanced Search

Browse

My Account

Show simple item record

dc.contributor.author Graudins, A
dc.contributor.author Padula, M
dc.contributor.author Broady, K
dc.contributor.author Nicholson, GM
dc.date.accessioned 2009-12-21T02:33:48Z
dc.date.issued 2001
dc.identifier.citation Annals of Emergency Medicine, 2001, 37 (2), pp. 154 - 160
dc.identifier.issn 0196-0644
dc.identifier.other C1 en_US
dc.identifier.uri http://hdl.handle.net/10453/4522
dc.description.abstract Study objectives: Widow spiders of the genus Latrodectus are found worldwide and produce similar clinical envenomation syndromes. In Australia, red-back spider antivenom (RBS-AV) is effective therapy for Latrodectus hasselti envenomation and it has been reported to reverse envenomation by other widow spiders. This study assessed the efficacy of RBS-AV in preventing in vitro and in vivo toxicity of widow spider venoms of North America and Europe. Methods: The binding of RBS-AV to α-latrotoxin and Latrodectus venoms (Latrodectus spp mactans, hesperus, lugubris, tredecimguttatus, hasselt) was assayed using Western blotting. Prevention of in vitro toxicity to α-latrotoxin and the same venoms was tested by pretreating an isolated chick biventer cervicis nerve-muscle preparation with RBS-AV. Prevention of in vivo toxicity was determined by a lethality study in male Balb/c mice to (2.5 to 5× median lethal dose [LD50]) or α-latrotoxin (10× LD50) preincubated with antivenom or without RBS-AV (control). Results: In Western blots, RBS-AV bound to α-latrotoxin and similar widow spider proteins in all venoms tested, indicating antigenic similarity with proteins found in RBS venom. Antivenom prevented the typical in vitro muscle contracture and loss of twitch tension seen with α-latrotoxin and the venoms tested. Control mice rapidly developed signs of envenomation, but mice treated with RBS-AV remained free of signs of envenomation. Conclusion: RBS-AV prevented both in vitro and in vivo toxicity from Latrodectus venoms and α-latrotoxin in mice. These data suggest that RBS-AV may be clinically effective in the treatment of envenomation resulting from the bite of other widow spiders.
dc.language eng
dc.relation.isbasedon 10.1067/mem.2001.113033
dc.title Red-back spider (Latrodectus hasselti) antivenom prevents the toxicity of widow spider venoms
dc.type Journal Article
dc.description.version Published
dc.parent Annals of Emergency Medicine
dc.journal.volume 2
dc.journal.volume 37
dc.journal.number 2 en_US
dc.publocation USA en_US
dc.identifier.startpage 154 en_US
dc.identifier.endpage 160 en_US
dc.cauo.name SCI.Medical and Molecular Biosciences en_US
dc.conference Verified OK en_US
dc.for 110705 Humoural Immunology and Immunochemistry
dc.for 060101 Analytical Biochemistry
dc.personcode 004814
dc.personcode 970082
dc.personcode 870145
dc.personcode 850065
dc.percentage 60 en_US
dc.classification.name Analytical Biochemistry en_US
dc.classification.type FOR-08 en_US
pubs.embargo.period Not known
pubs.organisational-group /University of Technology Sydney
pubs.organisational-group /University of Technology Sydney/Faculty of Science
pubs.organisational-group /University of Technology Sydney/Strength - Health Technologies
utslib.copyright.status Closed Access
utslib.copyright.date 2015-04-15 12:17:09.805752+10
pubs.consider-herdc true
utslib.collection.history School of Medical and Molecular Sciences (ID: 341)
utslib.collection.history Closed (ID: 3)


Files in this item

This item appears in the following Collection(s)

Show simple item record